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(∆NTCP). In the Netherlands, a national consensus has been 
reached regarding the threshold for (∆NTCP  
Finally, the potential benefits of protons can be clinically 
validated in step 4, based on external validation of the NTCP-
models when patients are treated with protons. The model-
based approach is an evidence-based methods for selection 
and validation of new radiation technologies. 
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Synopsis:  
In thoracic irradiation, the maximum radiation dose is 
restricted by the risk of radiation-induced cardiopulmonary 
damage and dysfunction limiting tumor control. 
Unfortunately, current clinical practice does not include 
preventative measures to attenuate radiation-induced lung or 
cardiac toxicity. Inhibition of the renin-angiotensin system 
(RAS) seems to be an alluring strategy for attenuating 
radiation-induced cardiopulmonary dysfunction.  
Interestingly, angiotensin-converting enzyme inhibitors (ACEi) 
have been shown to reduce the risk of radiation-induced 
respiratory dysfunction in preclinical (1) and clinical studies 
(2). More recently a study in rats showed that ACEi reduces 
respiratory dysfunction indirectly by reducing acute heart 
damage (3).  
So far, the mechanisms of the protective effect of ACEi on 
radiation-induced toxicity are not clear. Apart from their 
hypotensive action, ACEi are known to have other properties 
such as an anti-inflammatory action. Further, it has been 
suggested that the sulfhydryl group in the molecular 
structure of captopril confers in a free radical scavenger 
activity. All these effects can account in part for its 
radioprotection. Besides, it might act as an antioxidant to 
reduce inflammatory reactive oxygen species and thus 
mitigate radiation-induced toxicity.  
To conclude, ACE inhibitors have been shown to mitigate 
radiation-induced cardio-/pulmonary toxicity in (pre)clinical 
models. However, the mechanisms of action are not clear. As 
such the use of ACE inhibitors should be further evaluated as 
a strategy to reduce cardiopulmonary complications induced 
by radiotherapy to the thoracic area.  
1. Ghosh SN, Zhang R, Fish BL, et al. Renin-angiotensin 
system suppression mitigates experimental radiation 
pneumonitis. Int J Radiat Oncol Biol Phys 2009;75:1528-36.  
2. Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of 
radiation pneumonitis with incidental concurrent use of 
angiotensin-converting enzyme inhibitors and thoracic 
radiation therapy. Int J Radiat Oncol Biol Phys 2012;84:238-
43.  
3. van der Veen SJ, Ghobadi G, de Boer RA, et al. ACE 
inhibition attenuates radiation-induced cardiopulmonary 
damage. Radiother Oncol 2015;114:96-103. 
 
 
 
 
SP-0013 
Radiation-induced musculosqueletic late damages: possible 
clinical cure or simple mitigation? 
S. Delanian
1Hôpital Saint-Louis- APHP, Oncologie-Radiothérapie, Paris, 
France 
1 
 
RI musculo-squeletic sequelae combine opposite tissular 
aspects of fibrosis and atrophy in an heterogeneous 
patchwork comprising concomitant active cellular and 
sclerotic matricial areas. Tissue remodeling follow early, 
subacute, chronic inflammatory changes, then fibrosis and 
necrosis, that provides signaling pathways through growth 
factors and their receptors.  
In medicine, clinical cure of a chronic disease is never binary 
or surgical, if exists, because of the pathologic underground 
network well-established in the tissues.  
Cure for radiation-induced (RI) late damages should be 
approach by a strategy using a hierarchical control of 
accurate protagonists. During last decades, each therapeutic 
intervention has illustrated successively one of the facets of 
this fibrotic process:  
- In seventies, STEROIDS, then non anti-inflammatory drugs, 
showed able to stop acute RIF progression and are always 
required today as the first treatment in all sequelae, while 
anti-collagenic drugs were too toxic.  
- In eighties, vascular approach revealed antithrombotic help 
in some acute aspects (HEPARIN), and interesting role of 
PENTOXIFYLLINE (speed healing) or HBO.  
- In nineties, successful clinical use of superoxide dismutase 
(SOD) allowed to bring to light reactive oxygen species (ROS) 
- fibroblasts and their related anti-oxidant strategy, then 
PENTOXIFYLLINE-VITAMIN E (PE) combination. The fibrotic 
clinical regression was slow but measurable, followed by 
convincing “preclinical” studies (histological reversion, in 
vitro modulation): first cases of fibrotic clinical cure [1,2].  
- Then anticytokines (TGFβ, CTGF, …).  
- After 2000, adding clodronate, in a PENTOCLO combination, 
allowed speeder and durable clinical RI responses, 
highlighting its anti-macrophagic effect on bone necrosis : 
first cases of osteoradionecrosis clinical cure [3]. However, 
therapeutic range of these drugs is tight, related to 
bisphosphonate absence of specificity and the bivalent 
macrophagic action (M1/M2 populations).  
Clinical cure is a difficult art: it should take in account all 
these several facets. In the future, controlled trials and 
preclinical studies are necessary to identify best antifibrotic 
agents (phenotypic revesion of deficient cells), and organ 
specific targeted drugs and/or stem cell therapy (compensate 
tissular depletion after cell death), to obtain regular clinical 
cure if any.  
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